Cargando…
Can PPSV-23 Vaccine Impact Exacerbations of Chronic Cough Symptoms and Medication Use in Younger Adult Asthmatics? A Clinical Question That Needs Answering
Symptoms of chronic cough (CC) from the airways are commonly treated with antibiotics, antitussives, bronchodilators, and steroids. There is a wide variability in treatment response, dependent on the exact cough etiology. Our case-series study was composed of 71 nonsmoking adults, 59 females, mean a...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876381/ https://www.ncbi.nlm.nih.gov/pubmed/35214677 http://dx.doi.org/10.3390/vaccines10020219 |
_version_ | 1784658157024313344 |
---|---|
author | Lanz, Alessandra M. Chartrand, Esther Eisenlohr, Claudia P. Lanz, Miguel J. |
author_facet | Lanz, Alessandra M. Chartrand, Esther Eisenlohr, Claudia P. Lanz, Miguel J. |
author_sort | Lanz, Alessandra M. |
collection | PubMed |
description | Symptoms of chronic cough (CC) from the airways are commonly treated with antibiotics, antitussives, bronchodilators, and steroids. There is a wide variability in treatment response, dependent on the exact cough etiology. Our case-series study was composed of 71 nonsmoking adults, 59 females, mean age 43 (±21) years, with a history of CC-asthma and history of ≥2 exacerbations/year requiring systemic steroids and/or antibiotics. All had decreased Streptococcus pneumoniae antibody titers, with a mean average of 3 of 23 normal serotypes and were subsequently vaccinated with PPSV-23. Pre- and post-12-month vaccination questionnaires were administered, and 35 (54%) reported both decreased CC symptoms and asthma medication use. Baseline comparisons to those with no change in CC symptoms or asthma medication use revealed significantly lower exhaled nitric oxide (FeNO) levels (17 ± 10; 62 + 40 ppb), serum eosinophils (192 ± 156; 280 ± 166/mcL), and total IgE (132 ± 167; 275 ± 290 IU/mL) in those with improvement post-vaccination. Higher baseline symptoms scores for upper respiratory infections as a trigger to their CC (* p > 0.05) were found in those responding to PPSV-23. These data reveal a subset of asthma in younger adults, <65 years, with significantly decreased S. pneumoniae antibody titers with less CC symptoms and asthma medication use for exacerbations after PPSV-23 vaccination. |
format | Online Article Text |
id | pubmed-8876381 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88763812022-02-26 Can PPSV-23 Vaccine Impact Exacerbations of Chronic Cough Symptoms and Medication Use in Younger Adult Asthmatics? A Clinical Question That Needs Answering Lanz, Alessandra M. Chartrand, Esther Eisenlohr, Claudia P. Lanz, Miguel J. Vaccines (Basel) Communication Symptoms of chronic cough (CC) from the airways are commonly treated with antibiotics, antitussives, bronchodilators, and steroids. There is a wide variability in treatment response, dependent on the exact cough etiology. Our case-series study was composed of 71 nonsmoking adults, 59 females, mean age 43 (±21) years, with a history of CC-asthma and history of ≥2 exacerbations/year requiring systemic steroids and/or antibiotics. All had decreased Streptococcus pneumoniae antibody titers, with a mean average of 3 of 23 normal serotypes and were subsequently vaccinated with PPSV-23. Pre- and post-12-month vaccination questionnaires were administered, and 35 (54%) reported both decreased CC symptoms and asthma medication use. Baseline comparisons to those with no change in CC symptoms or asthma medication use revealed significantly lower exhaled nitric oxide (FeNO) levels (17 ± 10; 62 + 40 ppb), serum eosinophils (192 ± 156; 280 ± 166/mcL), and total IgE (132 ± 167; 275 ± 290 IU/mL) in those with improvement post-vaccination. Higher baseline symptoms scores for upper respiratory infections as a trigger to their CC (* p > 0.05) were found in those responding to PPSV-23. These data reveal a subset of asthma in younger adults, <65 years, with significantly decreased S. pneumoniae antibody titers with less CC symptoms and asthma medication use for exacerbations after PPSV-23 vaccination. MDPI 2022-01-30 /pmc/articles/PMC8876381/ /pubmed/35214677 http://dx.doi.org/10.3390/vaccines10020219 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Lanz, Alessandra M. Chartrand, Esther Eisenlohr, Claudia P. Lanz, Miguel J. Can PPSV-23 Vaccine Impact Exacerbations of Chronic Cough Symptoms and Medication Use in Younger Adult Asthmatics? A Clinical Question That Needs Answering |
title | Can PPSV-23 Vaccine Impact Exacerbations of Chronic Cough Symptoms and Medication Use in Younger Adult Asthmatics? A Clinical Question That Needs Answering |
title_full | Can PPSV-23 Vaccine Impact Exacerbations of Chronic Cough Symptoms and Medication Use in Younger Adult Asthmatics? A Clinical Question That Needs Answering |
title_fullStr | Can PPSV-23 Vaccine Impact Exacerbations of Chronic Cough Symptoms and Medication Use in Younger Adult Asthmatics? A Clinical Question That Needs Answering |
title_full_unstemmed | Can PPSV-23 Vaccine Impact Exacerbations of Chronic Cough Symptoms and Medication Use in Younger Adult Asthmatics? A Clinical Question That Needs Answering |
title_short | Can PPSV-23 Vaccine Impact Exacerbations of Chronic Cough Symptoms and Medication Use in Younger Adult Asthmatics? A Clinical Question That Needs Answering |
title_sort | can ppsv-23 vaccine impact exacerbations of chronic cough symptoms and medication use in younger adult asthmatics? a clinical question that needs answering |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876381/ https://www.ncbi.nlm.nih.gov/pubmed/35214677 http://dx.doi.org/10.3390/vaccines10020219 |
work_keys_str_mv | AT lanzalessandram canppsv23vaccineimpactexacerbationsofchroniccoughsymptomsandmedicationuseinyoungeradultasthmaticsaclinicalquestionthatneedsanswering AT chartrandesther canppsv23vaccineimpactexacerbationsofchroniccoughsymptomsandmedicationuseinyoungeradultasthmaticsaclinicalquestionthatneedsanswering AT eisenlohrclaudiap canppsv23vaccineimpactexacerbationsofchroniccoughsymptomsandmedicationuseinyoungeradultasthmaticsaclinicalquestionthatneedsanswering AT lanzmiguelj canppsv23vaccineimpactexacerbationsofchroniccoughsymptomsandmedicationuseinyoungeradultasthmaticsaclinicalquestionthatneedsanswering |